Statin Potency Modulates Protective Effects Against AMD

While more than a dozen research papers have evaluated the association between statin use and risk of AMD, their results are contradicting. These inconsistencies could be explained by the intensity-dependent reduction in AMD risk observed in a recent study, which warrants future randomized trials that stratify analyses by statin potency. Photo: Mo Rafieetary, OD. Click image to enlarge. The popularity of statins for the management of hyperlipidemia and the prevention of cardiovascular disease make them a common occurrence in a patient’s medical history. The lipid-lowering, anti-inflammatory agents may also be protective against non-cardiovascular conditions, including age-related macular degeneration, some studies show, though statin potency is thought to modulate this relationship. A new study, published on Sunday in American Journal of Ophthalmology, aimed to investigate how differing intensities of statin therapy—high, moderate and low—affect the progression of AMD among patients with type 2 diabetes and dyslipidemia. Their findings revealed that while high- and medium-intensity statins significantly reduced AMD risk, weaker agents failed to show an association. The retrospective clinical cohort study analyzed electronic health records from the TriNetX US Collaborative Network spanning from 2014 to 2024. The cohort included 20,282 adults aged 40 years and older diagnosed with type 2 diabetes and dyslipidemia who had at least one ophthalmologic visit. Patients with confounding conditions such as liver disease or a previous history of AMD were excluded. Aside from a statin-naïve cohort, all other participants had at least five years of documented statin use. All cohorts were matched for age, gender, systemic comorbidities and stage of diabetic retinopathy. High-, medium- and low-intensity statin exposure were defined as follows:High-intensity: rosuvastatin at doses of 20mg to 40mg, atorvastatin at doses of 40mg to 80mg.Medium-intensity: rosuvastatin at 5mg or 10mg, simvastatin at 20mg or 40mg, fluvastatin at 80mg, pravastatin at 40mg or 80mg, lovastatin at 40mg, atorvastatin at 10mg or 20mg, pitavastatin at 1mg, 2mg or 4mgLow-intensity: simvastatin at 5mg or 10mg, pravastatin at 10mg or 20mg, lovastatin at 10mg or 20mg, fluvastatin at 20mg or 40mgHigh-intensity statin users exhibited a significant reduction in the risk of developing AMD at both three years (hazard ratio, HR: 0.74) and five years (HR: 0.79) when compared to the statin-naïve cohort. Similarly, patients on medium-intensity statin therapy also demonstrated a decreased risk of exudative or nonexudative AMD (HR: 0.49) at all time points. In contrast, those taking low-intensity statins did not show any statistically significant correlation with a reduction in AMD risk; however, this group did maintain a survival advantage via reduction of all-cause mortality, similar to the high- and medium-intensity statin exposure groups.“Despite over 14 population-based and case-control studies, and six randomized clinical trials, the association between statin use and risk of AMD remains controversial,” the researchers explained in their paper. They noted that while some prior investigations have observed a protective effect of statins on AMD, others failed to find a correlation. “We found an intensity-dependent reduction in AMD risk, potentially explaining the inconsistencies in prior studies,” the researchers surmised. This study also offers the advantage of a longer follow-up period (five years) than employed in prior studies (one to three years). While high-intensity statin therapy appears to provide the greatest benefit for AMD prevention, the researchers emphasize the importance of considering the drug’s safety profile, especially at a higher potency. “High-intensity statin use, while generally well-tolerated, carries a small risk of serious adverse effects, including statin-associated muscle injury (rhabdomyolysis) with potential acute kidney injury, as well as hepatic toxicity,” they noted. Therefore, they urge clinicians to “balance the benefits of high-intensity statin use with these rare but significant risks when interpreting our findings and applying them to patient care.”Limitations of the study include its retrospective design, which made it impossible to evaluate patient adherence to statin use. Furthermore, AMD cases reported in this study may be subject to underestimation, since “patients who received eye care outside participating health systems could be missing AMD diagnoses in our data,” the researchers pointed out.“In conclusion,” the authors wrote, “our study highlights the differential effects of statin intensities on AMD outcomes, providing evidence that high- and medium-, but not low-intensity statins could be beneficial in preventing AMD progression, in patients with type 2 diabetes.” To elucidate the role of statins in AMD management, they argued the need for “large-scale, randomized trials with stratified analyses by statin intensity and patient comorbidity profiles,” such as cardiovascular disease and diabetes severity.Click here for the journal source. Hussain ZS, Chauhan MZ, Muayad J, et al. Potency matters: the role of statin intensity in modulating risk for age-related macular degeneration. Am J Ophthalmol. August 17, 2025. [Epub ahead of print]. This article was developed by the editorial staff in conjunction with experts in the field. In the process, AI may have been among the editorial tools used to meet the goals of human editors, who approved all content.